Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Cervical Pain, Pelvic Pain
Interventions: Nitroprusside Gel, Placebo Gel; Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: QT/QTc Interval in Healthy Volunteers
Interventions: WCK 5222, IV placebo matched to WCK 5222 / Moxifloxacin IV solution, Moxifloxacin 400-mg; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Healthy
Interventions: cangrelor, moxifloxacin, placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Alzheimer's Disease
Interventions: Telmisartan 20mg, Telmisartan 40mg, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 30 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acne Inversa
Interventions: PF-06650833, PF-06700841, PF-06826647, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 63
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 42 more

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: shark cartilage extract AE-941, placebo, cisplatin, vinorelbine tartrate, carboplatin, paclitaxel, radiation therapy; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Interventions: TPN-101, 400 mg/day, Placebo; Drug
Lead sponsor: Transposon Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: La Jolla, California • Orange, California • San Francisco, California + 5 more

Conditions: Schistosomiasis
Interventions: Placebo, Sm-TSP-2/Alhydrogel, Sm-TSP-2/Alhydrogel/GLA-AF; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza, Human, Influenza in Birds, Respiratory Tract Infections, Infections, Orthomyxoviridae Infections, RNA Virus Infections, Virus Diseases, Respiratory Tract Diseases
Interventions: aH5N6c on Day 1, aH5N6c on Day 22, Placebo on Day 22; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 18
States / cities: Huntsville, Alabama • Tempe, Arizona • San Diego, California + 14 more

Conditions: Smoking Cessation
Interventions: AXS-05 (dextromethorphan-bupropion), Bupropion, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 28
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Lemon Grove, California + 24 more

Conditions: Colorectal Cancer, Precancerous Condition
Interventions: rosuvastatin, placebo; Drug · Other
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 584
States / cities: Anniston, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 423 more

Conditions: Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
Interventions: Elenestinib, Placebo; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 15
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 12 more

Conditions: Generalized Lipodystrophy
Interventions: Placebo, Low-Dose REGN4461, High-dose REGN4461; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Bethesda, Maryland • Ann Arbor, Michigan • Dallas, Texas

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: Metformin, Placebo; Drug · Other
Lead sponsor: Kyongtae Ty Bae, M.D., Ph.D.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Obesity
Interventions: Coffee mannooligosaccharide, Coffee mannooligosaccharides; Dietary Supplement
Lead sponsor: Mondelēz International, Inc.; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Invasive Fungal Infections
Interventions: Micafungin, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 16 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 41
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 32 more

Conditions: Liver Cirrhosis, Sarcopenia
Interventions: LPCN 1148, Placebo; Drug
Lead sponsor: Lipocine Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 6 more

Conditions: Diabetes Mellitus, Diabetes Type 1
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 35 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Coronavirus Disease (COVID-19)
Interventions: Molnupiravir, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 20
States / cities: Harbor City, California • Los Angeles, California • Sacramento, California + 17 more

Conditions: Contraceptive Devices, Long-Acting Reversible Contraception, Analgesia, Adolescent Health, Gynecology
Interventions: Nitrous oxide gas for inhalation, Oxygen Gas for Inhalation; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 14 Years to 24 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Barzolvolimab, Matching placebo; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 33
States / cities: Birmingham, Alabama • Beverly Hills, California • Burbank, California + 28 more

Conditions: Human Immunodeficiency Virus
Interventions: TMB-607, Placebo; Drug
Lead sponsor: TaiMed Biologics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Myocardial Bridging
Interventions: Nebivolol, Diltiazem, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cerebral Palsy, GERD
Interventions: Baclofen, placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 3 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

The Effect of Nitroprusside on Intrauterine Device (IUD) Insertion

Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers

Health Evaluation in African Americans Using RAS Therapy

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease

Study of Coffee Mannooligosaccharides for Weight Management

Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU

A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

ACZ885 in Type 1 Diabetes Mellitus

Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)

Nitrous Oxide for Pain Management During IUD Insertion in Nulliparous Adolescent Women

A Study of Barzolvolimab in Patients With Atopic Dermatitis

Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy